Nonendocrine Pathways and Endocrine Resistance: Observations with Antiestrogens and Signal Transduction Inhibitors in Combination

Robert I. Nicholson, Iain R. Hutcheson, Janice M. Knowlden, Helen E. Jones, Maureen E. Harper, Nicola Jordan, Steve E. Hiscox, Denise Barrow, Julia M W Gee, Mina Bissell, Myles Brown, James Ingle, Jeffrey Green, Carlos Arteaga, Matthew Ellis, Richard Santen

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

An increasing body of evidence demonstrates that growth factor networks are highly interactive with estrogen receptor signaling in the control of breast cancer growth. As such, tumor responses to antiestrogens are likely to be a composite of the estrogen receptor and growth factor-inhibitory activity of these agents, with alterations/aberrations in growth factor signaling providing a mechanism for the development of antiestrogen resistance. In this light, the current article focuses on illustrating the relationship between growth factor signaling and antiestrogen failure in our in-house tumor models of breast cancer and describing how we are now beginning to successfully target growth factor activity to improve the effects of antiestrogen drugs and to block aggressive disease progression.

Original languageEnglish (US)
JournalClinical Cancer Research
Volume10
Issue number1 II
DOIs
StatePublished - Jan 28 2004
Externally publishedYes

Fingerprint

Estrogen Receptor Modulators
Signal Transduction
Intercellular Signaling Peptides and Proteins
Estrogen Receptors
Breast Neoplasms
Disease Progression
Neoplasms
Growth
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nonendocrine Pathways and Endocrine Resistance : Observations with Antiestrogens and Signal Transduction Inhibitors in Combination. / Nicholson, Robert I.; Hutcheson, Iain R.; Knowlden, Janice M.; Jones, Helen E.; Harper, Maureen E.; Jordan, Nicola; Hiscox, Steve E.; Barrow, Denise; Gee, Julia M W; Bissell, Mina; Brown, Myles; Ingle, James; Green, Jeffrey; Arteaga, Carlos; Ellis, Matthew; Santen, Richard.

In: Clinical Cancer Research, Vol. 10, No. 1 II, 28.01.2004.

Research output: Contribution to journalArticle

Nicholson, RI, Hutcheson, IR, Knowlden, JM, Jones, HE, Harper, ME, Jordan, N, Hiscox, SE, Barrow, D, Gee, JMW, Bissell, M, Brown, M, Ingle, J, Green, J, Arteaga, C, Ellis, M & Santen, R 2004, 'Nonendocrine Pathways and Endocrine Resistance: Observations with Antiestrogens and Signal Transduction Inhibitors in Combination', Clinical Cancer Research, vol. 10, no. 1 II. https://doi.org/10.1158/1078-0432.CCR-031206
Nicholson, Robert I. ; Hutcheson, Iain R. ; Knowlden, Janice M. ; Jones, Helen E. ; Harper, Maureen E. ; Jordan, Nicola ; Hiscox, Steve E. ; Barrow, Denise ; Gee, Julia M W ; Bissell, Mina ; Brown, Myles ; Ingle, James ; Green, Jeffrey ; Arteaga, Carlos ; Ellis, Matthew ; Santen, Richard. / Nonendocrine Pathways and Endocrine Resistance : Observations with Antiestrogens and Signal Transduction Inhibitors in Combination. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 1 II.
@article{3d3a88aca93243c0835a5df73ebc9f23,
title = "Nonendocrine Pathways and Endocrine Resistance: Observations with Antiestrogens and Signal Transduction Inhibitors in Combination",
abstract = "An increasing body of evidence demonstrates that growth factor networks are highly interactive with estrogen receptor signaling in the control of breast cancer growth. As such, tumor responses to antiestrogens are likely to be a composite of the estrogen receptor and growth factor-inhibitory activity of these agents, with alterations/aberrations in growth factor signaling providing a mechanism for the development of antiestrogen resistance. In this light, the current article focuses on illustrating the relationship between growth factor signaling and antiestrogen failure in our in-house tumor models of breast cancer and describing how we are now beginning to successfully target growth factor activity to improve the effects of antiestrogen drugs and to block aggressive disease progression.",
author = "Nicholson, {Robert I.} and Hutcheson, {Iain R.} and Knowlden, {Janice M.} and Jones, {Helen E.} and Harper, {Maureen E.} and Nicola Jordan and Hiscox, {Steve E.} and Denise Barrow and Gee, {Julia M W} and Mina Bissell and Myles Brown and James Ingle and Jeffrey Green and Carlos Arteaga and Matthew Ellis and Richard Santen",
year = "2004",
month = "1",
day = "28",
doi = "10.1158/1078-0432.CCR-031206",
language = "English (US)",
volume = "10",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1 II",

}

TY - JOUR

T1 - Nonendocrine Pathways and Endocrine Resistance

T2 - Observations with Antiestrogens and Signal Transduction Inhibitors in Combination

AU - Nicholson, Robert I.

AU - Hutcheson, Iain R.

AU - Knowlden, Janice M.

AU - Jones, Helen E.

AU - Harper, Maureen E.

AU - Jordan, Nicola

AU - Hiscox, Steve E.

AU - Barrow, Denise

AU - Gee, Julia M W

AU - Bissell, Mina

AU - Brown, Myles

AU - Ingle, James

AU - Green, Jeffrey

AU - Arteaga, Carlos

AU - Ellis, Matthew

AU - Santen, Richard

PY - 2004/1/28

Y1 - 2004/1/28

N2 - An increasing body of evidence demonstrates that growth factor networks are highly interactive with estrogen receptor signaling in the control of breast cancer growth. As such, tumor responses to antiestrogens are likely to be a composite of the estrogen receptor and growth factor-inhibitory activity of these agents, with alterations/aberrations in growth factor signaling providing a mechanism for the development of antiestrogen resistance. In this light, the current article focuses on illustrating the relationship between growth factor signaling and antiestrogen failure in our in-house tumor models of breast cancer and describing how we are now beginning to successfully target growth factor activity to improve the effects of antiestrogen drugs and to block aggressive disease progression.

AB - An increasing body of evidence demonstrates that growth factor networks are highly interactive with estrogen receptor signaling in the control of breast cancer growth. As such, tumor responses to antiestrogens are likely to be a composite of the estrogen receptor and growth factor-inhibitory activity of these agents, with alterations/aberrations in growth factor signaling providing a mechanism for the development of antiestrogen resistance. In this light, the current article focuses on illustrating the relationship between growth factor signaling and antiestrogen failure in our in-house tumor models of breast cancer and describing how we are now beginning to successfully target growth factor activity to improve the effects of antiestrogen drugs and to block aggressive disease progression.

UR - http://www.scopus.com/inward/record.url?scp=9144251561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144251561&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-031206

DO - 10.1158/1078-0432.CCR-031206

M3 - Article

C2 - 14734490

AN - SCOPUS:9144251561

VL - 10

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1 II

ER -